James K Mangan
Overview
Explore the profile of James K Mangan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah B, Mattison R, Abboud R, Abdelmessieh P, Aldoss I, Burke P, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):563-576.
PMID: 39413812
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based...
2.
Vaidya P, Wang H, Don M, Hinds B, Mangan J
Leuk Res Rep
. 2024 Jan;
21:100408.
PMID: 38269085
Near early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare hematologic malignancy, for which second line therapeutic options are limited. T-cell leukemias are also rarely associated with leukemia cutis,...
3.
Stein E, Fathi A, Harb W, Colak G, Fusco A, Mangan J
Leuk Lymphoma
. 2024 Jan;
65(4):503-510.
PMID: 38259250
Pelabresib (CPI-0610), a BET protein inhibitor, is in clinical development for hematologic malignancies, given its ability to target NF-κB gene expression. The MANIFEST phase 1 study assessed pelabresib in patients...
4.
Aldoss I, Tizro P, Bedi D, Mangan J, Clark M, Spencer D, et al.
Haematologica
. 2023 Jul;
108(12):3511-3516.
PMID: 37470155
No abstract available.
5.
Connor M, Loren A, Hexner E, Martin M, Gill S, Luger S, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):113-118.
PMID: 36336258
Patients with refractory or relapsed and refractory myeloid malignancies have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) in patients with active, chemotherapy-refractory myeloid disease is...
6.
Lee A, Goodman A, Mangan J
Case Rep Hematol
. 2022 May;
2022:2802680.
PMID: 35515507
Acute myeloid leukemia (AML) is associated with particularly poor outcomes in the elderly population, in whom the disease is most prevalent. BCL-2 has been identified as an antiapoptotic protein and...
7.
Freyer C, Carulli A, Gier S, Ganetsky A, Timlin C, Schuster M, et al.
Leuk Lymphoma
. 2022 Feb;
63(8):1925-1933.
PMID: 35188052
Patients undergoing haploidentical or mismatched unrelated donor (haplo/MMUD) allogeneic hematopoietic cell transplantation (alloHCT) receiving post-transplant cyclophosphamide (PTCy) are at high risk of cytomegalovirus (CMV) infection. Experience with letermovir (LET) in...
8.
Novatcheva E, Anouty Y, Saunders I, Mangan J, Goodman A
Clin Lymphoma Myeloma Leuk
. 2021 Oct;
22(3):e161-e184.
PMID: 34649791
Acute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously...
9.
Freyer C, Gier S, Moyer M, Berryman N, Carulli A, Ganetsky A, et al.
Transplant Cell Ther
. 2021 May;
27(5):431.e1-431.e8.
PMID: 33965188
Oropharyngeal mucositis (OPM) is common following conditioning for allogeneic hematopoietic cell transplantation (alloHCT) and results in pain, functional status decline, need for nutritional support, infections, and prolonged length of stay...
10.
Freyer C, Carulli A, Ganetsky A, Hughes M, Krause T, Timlin C, et al.
Leuk Lymphoma
. 2020 Jun;
61(9):2200-2207.
PMID: 32482107
Pegaspargase (PEG) increases venous thromboembolism (VTE) in acute lymphoblastic leukemia (ALL) potentially due to depletion of anticoagulation factors, including antithrombin (AT). The benefit and cost of AT supplementation in adults...